Arrowhead Pharmaceuticals, Inc. (arwr)
ARWR Financials
| Trailing P/E | N/A |
| Forward P/E | -13.94 |
| Price/Sales | 14.09 |
| Price/Book | 20.30 |
| Market cap | $9.46B |
| Avg volume | 2202973.0 |
| Shares outstanding | 141254467.0 |
Start Free — open ARWR in Vest Terminal
Access live data, filings, ownership, and analysis for Arrowhead Pharmaceuticals, Inc..
Arrowhead Pharmaceuticals, Inc. FAQ
What does Arrowhead Pharmaceuticals, Inc. (ARWR) do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in P…
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does ARWR pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ARWR in?
Arrowhead Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is ARWR's market capitalization?
Approximate market cap: $9.46B.
What are the main risks for ARWR?
Key risks include above-average volatility (beta 1.28), among factors on this page.
What are the strengths of ARWR?
Potential positives include revenue growth of 1.7% year-over-year, gross margin of 100.0% supports competitive unit economics.
Where can I get analyst estimates for ARWR?
Public analyst price targets and consensus for Arrowhead Pharmaceuticals, Inc. are on the free /stocks/arwr/estimates page. Deeper estimate history and models are available in Vest Terminal.